Decoding the Epigenome of Breast Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26062605 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Elisa Cortellesi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Epigenesis, Genetic, Epigenome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 297 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tor Vergata University of Rome—Progetti Ricerca Scientifica d’Ateneo 2021 n°, “Progetto cellule staminali” NAST Centre.
Abstract (Originalsprache)
Breast cancer (BC) is the most prevalent malignancy among women, characterized by extensive heterogeneity stemming from molecular and genetic alterations. This review explores the intricate epigenetic landscape of BC, highlighting the significant role of epigenetic modifications—particularly DNA methylation, histone modifications, and the influence of non-coding RNAs—in the initiation, progression, and prognosis of the disease. Epigenetic alterations drive crucial processes, including gene expression regulation, cell differentiation, and tumor microenvironment interactions, contributing to tumorigenesis and metastatic potential. Notably, aberrations in DNA methylation patterns, including global hypomethylation and hypermethylation of CpG islands, have been associated with distinct BC subtypes, with implications for early detection and risk assessment. Furthermore, histone modifications, such as acetylation and methylation, affect cancer cell plasticity and aggressiveness by profoundly influencing chromatin dynamics and gene transcription. Finally, non-coding RNAs contribute by modulating epigenetic machinery and gene expression. Despite advances in our knowledge, clinical application of epigenetic therapies in BC is still challenging, often yielding limited efficacy when used alone. However, combining epi-drugs with established treatments shows promise for enhancing therapeutic outcomes. This review underscores the importance of integrating epigenetic insights into personalized BC treatment strategies, emphasizing the potential of epigenetic biomarkers for improving diagnosis, prognosis, and therapeutic response in affected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy.
- NAST Centre (Nanoscience & Nanotechnology & Innovative Instrumentation), Tor Vergata University of Rome, 00133 Rome, Italy.
ORCID-Profile: Elisa Cortellesi, Isabella Savini, Matteo Veneziano, Maria Valeria Catani, Valeria Gasperi
Förderung
- Tor Vergata University of Rome—Progetti Ricerca Scientifica d’Ateneo 2021 n°
- “Progetto cellule staminali” NAST Centre
Zitieren
APA
Cortellesi, E., Savini, I., Veneziano, M., Gambacurta, A., Catani, M. V., & Gasperi, V. (2025). Decoding the Epigenome of Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062605
Vancouver
Cortellesi E, Savini I, Veneziano M, Gambacurta A, Catani MV, Gasperi V. Decoding the Epigenome of Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062605
BibTeX
@article{Cortellesi2025,
author = {Cortellesi, Elisa and Savini, Isabella and Veneziano, Matteo and Gambacurta, Alessandra and Catani, Maria Valeria and Gasperi, Valeria},
title = {Decoding the Epigenome of Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26062605}
}
EUVIMED